Stemline Therapeutics Inc (NASDAQ:STML) – Investment analysts at Wedbush decreased their FY2018 earnings per share (EPS) estimates for Stemline Therapeutics in a research note issued to investors on Monday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($2.75) per share for the year, down from their previous forecast of ($2.69). Wedbush currently has a “Outperform” rating and a $22.00 price objective on the stock. Wedbush also issued estimates for Stemline Therapeutics’ Q4 2018 earnings at ($0.67) EPS, Q1 2019 earnings at ($0.52) EPS, Q2 2019 earnings at ($0.46) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($1.86) EPS, FY2020 earnings at ($1.35) EPS and FY2021 earnings at ($0.31) EPS.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06).

A number of other brokerages have also recently commented on STML. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 14th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research note on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $31.00.

Shares of Stemline Therapeutics stock opened at $11.37 on Thursday. Stemline Therapeutics has a 52 week low of $11.08 and a 52 week high of $20.55. The company has a market capitalization of $391.47 million, a price-to-earnings ratio of -3.87 and a beta of 0.58.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in Stemline Therapeutics by 6.3% in the third quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after acquiring an additional 116,672 shares during the period. Nexthera Capital LP boosted its position in shares of Stemline Therapeutics by 4.0% during the third quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock valued at $9,662,000 after buying an additional 22,553 shares during the last quarter. Northern Trust Corp boosted its position in shares of Stemline Therapeutics by 12.5% during the second quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock valued at $6,106,000 after buying an additional 42,262 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Stemline Therapeutics by 20.9% during the third quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock valued at $4,316,000 after buying an additional 45,000 shares during the last quarter. Finally, C WorldWide Group Holding A S boosted its position in shares of Stemline Therapeutics by 25.7% during the second quarter. C WorldWide Group Holding A S now owns 213,706 shares of the biopharmaceutical company’s stock valued at $3,430,000 after buying an additional 43,711 shares during the last quarter. 67.03% of the stock is owned by hedge funds and other institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Further Reading: Diversification in Investing

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.